PHILADELPHIA — Researchers from the Perelman School of Medicine at the University of Pennsylvania demonstrate for the first time that the immune system influences the skin microbiome. A new study found that the skin microbiome – a collection of microorganisms inhabiting the human body – is governed, at least in part, by an ancient branch of the immune system called complement. In turn, it appears microbes on the skin tweak the complement system, as well as immune surveillance of the skin. They found that complement may, in part, be responsible for maintaining a diverse set of microbes on our skin and keeping our skin healthy, which could play a role in a host of skin diseases.
Penn researchers Elizabeth Grice, PhD, assistant professor of Dermatology, and John Lambris, PhD, the Dr. Ralph and Sallie Weaver Professor of Research Medicine in the Department of Pathology and Laboratory Medicine, published findings in the August 26 issue of the Proceedings of the National Academy of Sciences.
Commensal, non-pathogenic bacteria that live on the skin provide an important service to their host, blocking pathogenic microbes from gaining a foothold, among other functions. In previous research, Grice and colleagues illuminated the great diversity of bacteria living on the skin using DNA-based sequence analysis of bacterial genes. However, until this study, very little was known about how the immune system influences those populations of bacteria living on the skin.
The complement system is like a molecular alarm system and first responder, Grice explains. “It leads the counterattack against microbial insult.” The system is an evolutionarily ancient branch of the immune response and a key function is marking microbial and dying host cells for elimination.
Complement also has inflammatory functions, and the team explored the relationship between the signaling of one particular inflammatory protein of the complement cascade, C5aR (the C5a receptor), and the skin microbiome. Their findings highlight a previously unrecognized role for complement on the skin.
The team treated one group of mice with an inhibitor of C5aR, and another with an inactive analog and compared the animals’ skin microbiome before and after treatment, based on DNA sequence analysis. They found that while the absolute number of microbes on the skin remained unchanged, the population diversity shifts in animals treated with a C5aR inhibitor compared to those who were not, with some groups of organisms increasing in abundance and others petering out.
The team also looked at the impact of C5aR inhibitor treatment on the immune system itself. They found that genes associated with immune surveillance were downregulated in the skin in inhibitor-treated animals, as was the number of immune cells overall.
Those results suggest that the complement system somehow influences the microbiome. To see if the effect also works in reverse, the team asked whether mice grown in a germ-free environment would express genes encoding complement components differently than mice grown under normal conditions. The microbiome did modulate the immune system: the animals grown in germ-free conditions expressed complement genes at lower levels in the skin than control animals.
“There’s a balance between the microbiome and the immune system,” Grice concludes. “Decreased microbial diversity has been associated with skin diseases such as atopic dermatitis, a type of eczema. Complement may in part be responsible for maintaining that diversity and keeping our skin healthy.”
And that’s important, she says, because it is becoming increasingly evident that many diseases are caused (or at least exacerbated) not by pathogens per se, but by “dysbiosis,” an imbalance in the microbial community.
“That balance is probably highly evolved so our optimal skin health is maintained when these two factors are in balance and communicating. And it’s when you disrupt one of those components that you can trigger or exacerbate a skin disorder or infection.”
Such a symbiotic relationship has already been documented in the gut.
While this study did not address the cause and effect between host and microbe, this interaction ultimately represents a potential therapeutic target, Grice says. If researchers can work out the skin microbiome and its relationship with complement, they might be able to tweak the microbial population one way or another to, for instance, modulate complement activation in patients with diseases that are in part caused by dysregulated or dysfunctional signaling, for example, psoriasis.
On the other hand, complement inhibitors, such as those being developed by Lambris’ lab and some of which are in clinical trials, may be used to therapeutically manipulate the skin microbiome back to a “healthy,” less dysbiotic state.
Now, Grice says, her team is working to better understand the mechanism of the complement-microbiome interaction, as well as its relationship to normal skin health and pathogenesis.
“I think our definition and labeling of ‘bad microbes’ needs to change,” Grice says. “We need to think about how we nurture our microbes rather than eradicate them. They evolved with us for a reason.”
Co-authors include Christel Chehoud, Stavros Rafail, Amanda S. Tyldsley, and John T. Seykora, all from Penn.
This work was supported by grants from the National Institute of Allergy and Infectious Diseases (NIAID) and the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) (AR060873, AI068730, AI095466, AI09560, AI097333, U01 AI095608, AR057217) and the University of Pennsylvania Skin Disease Research Center.
Penn Medicine is one of the world's leading academic medical centers, dedicated to the related missions of medical education, biomedical research, and excellence in patient care. Penn Medicine consists of the Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania (founded in 1765 as the nation's first medical school) and the University of Pennsylvania Health System, which together form a $5.3 billion enterprise.
The Perelman School of Medicine has been ranked among the top five medical schools in the United States for the past 18 years, according to U.S. News & World Report's survey of research-oriented medical schools. The School is consistently among the nation's top recipients of funding from the National Institutes of Health, with $373 million awarded in the 2015 fiscal year.
The University of Pennsylvania Health System's patient care facilities include: The Hospital of the University of Pennsylvania and Penn Presbyterian Medical Center -- which are recognized as one of the nation's top "Honor Roll" hospitals by U.S. News & World Report -- Chester County Hospital; Lancaster General Health; Penn Wissahickon Hospice; and Pennsylvania Hospital -- the nation's first hospital, founded in 1751. Additional affiliated inpatient care facilities and services throughout the Philadelphia region include Chestnut Hill Hospital and Good Shepherd Penn Partners, a partnership between Good Shepherd Rehabilitation Network and Penn Medicine.
Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities. In fiscal year 2015, Penn Medicine provided $253.3 million to benefit our community.
Department of Communications
For Patients and the General Public: